Blau Farmacêutica (B3: BLAU3) net income
Blau Farmacêutica reported a net profit of BRL 295.0m for fiscal 2025, 35.8% more than in fiscal 2024 (BRL 217.2m). Its net margin was 17.3%.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | BRL 295.0m | +35.8% | 17.3% |
| 2024 | BRL 217.2m | −13.1% | 12.4% |
| 2023 | BRL 249.8m | −31.3% | 18.2% |
| 2022 | BRL 363.4m | +11.7% | 25.8% |
| 2021 | BRL 325.2m | +27.9% | 23.8% |
| 2020 | BRL 254.3m | +27.0% | 21.5% |
| 2019 | BRL 200.2m | +62.5% | 20.5% |
| 2018 | BRL 123.3m | +19.5% | 15.8% |
| 2017 | BRL 103.1m | — | 16.7% |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.
Questions about the net income of Blau Farmacêutica
- How much did Blau Farmacêutica earn in fiscal 2025?
- Blau Farmacêutica reported a net profit of BRL 295.0m for fiscal 2025. In fiscal 2024 it reported a net profit of BRL 217.2m.
- What is the net margin of Blau Farmacêutica?
- In fiscal 2025 its net profit was 17.3% of its revenue.
- What was the most profitable year for Blau Farmacêutica?
- Of its last 9 fiscal years, fiscal 2022, with BRL 363.4m.
- Where do the figures for Blau Farmacêutica come from?
- From the annual financial statements (DFP) that Blau Farmacêutica files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual financial statements (DFP) that Blau Farmacêutica files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Blau Farmacêutica: the Blau Farmacêutica page · annual accounts · revenue · dividends paid.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.